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VITAMIN C: ATTENUATING EFFECT ON GROWTH 
AND PROLIFERATION IN SYSTEMIC MALIGNANCIES
S. Kapoor
Mechanicsville, VA 23111, USA
The recent article by J. Cha et al. provided for highly 
interesting reading [1].Vitamin C may attenuate tumor 
growth in a number of other systemic malignancies.
Vitamin C has a negative impact on tumor growth 
in breast cancers. Similarly it mitigates tumor me-
tastasis. It mediates this effect in part by attenuating 
IL-6 levels [2]. Similar effect is seen on VEGF levels. In-
terestingly, intravenous ascorbic acid has been shown 
to significantly improve the quality of life in breast can-
cer survivors during chemotherapy [3]. For instance, 
symptoms such as depression and nausea are mark-
edly decreased. Enhanced anti-proliferative effects 
are seen when vitamin C is administered in conjunction 
with agents such as retinoic acid [4]. In one recent 
study, the reported synergistic ratio of retinoic acid 
and vitamin C was 1.72. Vitamin C also augments the 
anti-neoplastic activity of chemotherapeutic agents 
such as cisplatin [5]. Similarly it increases the sentivity 
of breast cancer cells to agents such as doxorubicin.
Similar effects are seen in gastric malignancies. 
Vitamin C tends to augment intra-tumoral apoptosis. 
It mediates this effect by down-regulating 14–3–3σ via 
a mitochondrial dependent pathway [6]. Part of these 
pro-apoptotic effects are also mediated via p38-
MAP kinase-dependent up-regulation of transferrin 
receptor [7]. It also increases the Bax/ Bcl-xL ratio. 
These effects are dose dependent. Administration 
of vitamin C also augments superoxide dismutase 
activity. Vitamin C also enhances MHC class I expres-
sion by the cancerous cells [8]. At the same time Fas 
(CD95) expression is markedly augmented. As a result 
the sensitivity of cancer cells to anti-Fas antibodies 
is significantly accentuated.
Similarly, decreased RBC vitamin C levels have 
been noted in patients with prostate carcinomas. 
In fact, recent studies indicate that vitamin C mark-
edly attenuates tumor growth in hormone refractory 
prostatic malignancies [9]. It also has a negative im-
pact on tumor metastasis. Part of these effects are 
mediated via VEGF inhibition. At the same time vitamin 
C has an inhibitory effect on MMP-9 [10].
The above examples clearly highlight the significant 
anti-neoplastic effects of vitamin C.
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